Jan 20, 2022 | Featured, Medicare Part D, Statements
WASHINGTON — Patients Rising Executive Director Terry Wilcox today released the following statement regarding the Department of Health and Human Services’ new report on prescription drug affordability for Medicare Part D patients: “Action must be taken to make...
Read more
Jan 14, 2022 | Public Statement
Proposed decision will Exacerbate Health Inequities, Undermine FDA WASHINGTON — Patients Rising Executive Director Terry Wilcox today released the following statement regarding the Centers for Medicare and Medicaid Service proposed decision on the national coverage...
Read more
Jan 12, 2022 | Statements
WASHINGTON — Patients Rising Executive Director Terry Wilcox today released the following statement on last week’s proposed CMS Rule, touted to lower costs for Medicare Part D beneficiaries at the pharmacy counter by giving patients the pharmacy price concessions...
Read more
Jan 7, 2022 | FDA, Letters Submitted
The FDA’s Accelerated Approval Program provides a path for earlier approval of drugs being developed to treat serious diseases and address unmet medical need. The process allows the use of a surrogate endpoint—an indirect marker of clinical benefit that allows the...
Read more
Jan 7, 2022 | FDA, Letters Submitted
On behalf of Patients Rising, the organization representing millions of Americans living with chronic disease, I write to support the nomination of Dr. Robert Califf to serve as Commissioner of the Food and Drug Administration. The U.S. Food and Drug Administration...
Read more
